Skip to content
Open access

Dendrobine Attenuates Cisplatin-Induced Acute Kidney Injury with KEAP1–NRF2 Activation and Reduced Ferroptosis-Associated Stress

Oct 2026 · Antioxidants · Vol 15 · 0 citations · 40 references
Medicine

TL;DR

KEAP1–NRF2-regulated antioxidant defense as an important component of dendrobine-mediated protection against renal tubular injury and ferroptosis-associated stress in AKI is supported.

Abstract

Acute kidney injury (AKI) lacks effective pharmacological therapies, and ferroptosis-associated lipid peroxidation contributes to renal tubular injury. Here, we investigated the protective effects of dendrobine against AKI and its mechanisms. Dendrobine was evaluated in murine cisplatin-induced AKI and renal ischemia–reperfusion (I/R) models and in cisplatin- and erastin-challenged HK-2 cells using functional, histological, biochemical, and molecular analyses. Dendrobine improved renal function, alleviated tubular injury, reduced oxidative stress and lipid peroxidation, and preserved the GPX4/SLC7A11 antioxidant defense system in cisplatin-induced AKI and renal tubular cells. Dendrobine also attenuated erastin-associated lipid peroxidation and glutathione depletion, supporting an effect on ferroptosis-associated redox stress. Consistent renoprotective effects were observed in the renal I/R model. Mechanistically, target-engagement and protein-interaction analyses supported cellular engagement of KEAP1 by dendrobine and showed reduced KEAP1–NRF2 association and NRF2 ubiquitination, accompanied by enhanced NRF2 stabilization and nuclear accumulation. NRF2 inhibition attenuated the protective effects of dendrobine. Moreover, the KEAP1 R415A substitution attenuated dendrobine-associated KEAP1 engagement, NRF2 activation, and cytoprotection, supporting a functional contribution of Arg415 to these responses. Collectively, these findings support KEAP1–NRF2-regulated antioxidant defense as an important component of dendrobine-mediated protection against renal tubular injury and ferroptosis-associated stress in AKI.

Read PDF

Similar papers

Open access Sep 2026

Echinacoside Alleviates Cisplatin-Induced Acute Kidney Injury by Regulating Bap1 to Inhibit Ferroptosis

Background/Objectives: Cisplatin-induced acute kidney injury (AKI) is a major adverse complication restricting cisplatin-based chemotherapy. Ferroptosis contributes substantially to proximal tubular epithelial injury during AKI. This work aimed to explore the renoprotective effect of echinacoside (ECH) and its underlyi...

Li-Jia Chen, Ming-Jie Zhang, M. Chi et al. · 0 citations
Open access Oct 2026

Coptisine Protects Against Cisplatin‐Induced Acute Kidney Injury With Involvement of PI3K/Akt Signaling

Cisplatin is an effective chemotherapeutic agent whose clinical use is limited by nephrotoxicity. This study investigated the protective effects of coptisine, a bioactive alkaloid from Coptis chinensis, against cisplatin‐induced acute kidney injury (AKI). Network pharmacology was used to predict potential targets and p...

Chun-Yan Liu, Shu-Kun Chen, Ya-Ting He et al. · 0 citations
Open access Oct 2026

Melatonin attenuates diquat-induced acute liver injury by modulating Nrf2-Associated antioxidant signaling and ferroptosis-related processes.

ObjectiveDiquat (DQ) poisoning can cause severe acute liver injury associated with oxidative stress. This experimental animal study investigated the involvement of ferroptosis-related processes and Nrf2-associated antioxidant signaling in the protective effects of melatonin against DQ-induced liver injury.MethodsMale C...

Lei Xia, Guang-He Liu, Yun-Peng Duan et al. · 0 citations
Open access Sep 2026

Therapeutic Potential of Trilobatin in Cisplatin-Induced Kidney Injury: Targeting Ferroptosis and Inflammation

Cisplatin-induced acute kidney injury (CI-AKI) is a common and severe complication in cancer patients undergoing chemotherapy, which can progress to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Ferroptosis and inflammation are critical pathological mechanisms underlying CI-AKI. Trilobatin (TLB),...

Yang Xiang, Die Zhang, Qiang-Fang Dai et al. · 0 citations
Open access Sep 2026

A novel Keap1-Nrf2 inhibitor 6K delays the progression of AKI-to-CKD by mitigating maladaptive repair

It is demonstrated that Nrf2 deficiency exacerbates AKI-CKD progression through redox imbalance and ferroptosis-mediated maladaptive repair, and targeting Keap1-Nrf2 with 6K protects against renal injury and fibrosis, highlighting its therapeutic potential for kidney diseases.

Yi-Ming Wang, Yi Sun, Ting Zhou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.